Tytgat G N, Offerhaus G J, van Minnen A J, Everts V, Hensen-Logmans S C, Samson G
Gastroenterology. 1986 May;90(5 Pt 1):1111-20. doi: 10.1016/0016-5085(86)90375-6.
Histomorphometric, electron microscopic, and cell kinetic studies of gastric mucosa were performed in 12 healthy men treated with 100 micrograms of 15(R)-15-methyl prostaglandin E2 (PGE2) orally q.i.d. for 2 mo followed by 2 mo of placebo. Results were compared with 13 control subjects receiving placebo for 4 mo. After PGE2 administration, total antral mucosal thickness and antral and corpus foveolar thicknesses increased 36%, 44%, and 51%, respectively, over baseline values. The total number and height of the foveolar cells also increased. These morphologic changes reversed completely within 2 mo of stopping PGE2 therapy. After PGE2 administration, no evidence of mucosal inflammation or atypia was observed, nor was there any evidence of ultrastructural changes in the overall appearance of the parietal and gastrin cells. The increased thickness of the gastric mucosa could not be explained by alteration of the proliferative activity, as the labeling index and localization of the proliferative compartment remained unchanged after PGE2 therapy. Presumably PGE2 retards senescence and exfoliation of epithelial cells, which explains the foveolar expansion in the presence of unaltered proliferation.
对12名健康男性进行了胃黏膜的组织形态计量学、电子显微镜和细胞动力学研究。这些男性口服100微克15（R）-15-甲基前列腺素E2（PGE2），每日4次，持续2个月，随后服用2个月安慰剂。将结果与13名接受4个月安慰剂的对照受试者进行比较。给予PGE2后，胃窦黏膜总厚度、胃窦和胃体小凹厚度分别比基线值增加了36%、44%和51%。小凹细胞的总数和高度也增加了。停止PGE2治疗后2个月内，这些形态学变化完全逆转。给予PGE2后，未观察到黏膜炎症或异型性的证据，壁细胞和胃泌素细胞的整体超微结构外观也未出现任何变化。胃黏膜厚度增加不能用增殖活性的改变来解释，因为PGE2治疗后增殖指数和增殖区的定位保持不变。推测PGE2可延缓上皮细胞的衰老和脱落，这解释了在增殖未改变的情况下小凹的扩张。
